A process of dissolving [6,6]-phenyl-C.sub.60-butyric-N-2-dimethylaminoethyl ester in a solvent to produce a first mixture. A reagent is added to the first mixture to produce a second mixture. The second mixture is then refluxed to produce [6,6]-phenyl-C.sub.60-butyric-N-2-trimethylammonium ethyl ester iodide.

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

A chiral aryl propionic acid derivative and a pharmaceutical composition thereof, and a use. The chiral aryl propionic acid derivative is as shown in formula (I). The chiral aryl propionic acid derivative has antipyretic, analgesic and anti-inflammatory effects. The compound has high activity and can be locally administrated, a reduced dosage is expected, and adverse reactions are reduced.

##STR00001##

A chiral aryl propionic acid derivative and a pharmaceutical composition thereof, and a use. The chiral aryl propionic acid derivative is as shown in formula (I). The chiral aryl propionic acid derivative has antipyretic, analgesic and anti-inflammatory effects. The compound has high activity and can be locally administrated, a reduced dosage is expected, and adverse reactions are reduced.

##STR00001##

The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.

The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.